Myelodysplastic Syndrome Clinical Trial

International Registry for Severe Chronic Neutropenia

Summary

OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN).

II. Monitor and assess long term safety of primary treatment in SCN patients in the United States, Canada, Europe, and Australia.

III. Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly, cytogenetic abnormalities, myelodysplastic syndrome, and leukemia.

IV. Evaluate growth and development and hematologic parameters. V. Monitor for clinically significant changes in primary treatment response over time.

VI. Establish a physician network to increase the understanding of SCN. VII. Establish a demographic database to allow for future research.

View Full Description

Full Description

PROTOCOL OUTLINE:

Patients are treated by the referring physician as medically indicated. Clinical data are collected at baseline and then every 6 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria - Subjects are eligible for enrollment if they meet the following criteria:

A confirmed diagnosis of severe chronic neutropenia based on documented absolute neutrophil counts of less than 0.5x109/L on at least three occasions in the three months prior to enrollment.

For subjects with presumed cyclic neutropenia, documentation of at least two neutrophil cycles is preferred. Documentation should include the nadirs with neutrophil counts of less than 200 followed by a clear increase in the counts generally to at least 500 to 1000 followed by a second nadir, usually expected to occur at about three weeks after the first nadir, i.e., cycling with a three week periodicity. Documentation with at least six weeks of counts and two expected nadirs is preferred.

Cases not showing clear oscillations will be categorized as congenital (if neutropenia or neutropenic complications appear to have occurred from birth) or idiopathic (if all symptoms in evidence point to an acquired disorder occurring after the first year of life).

Bone marrow aspiration consistent with the diagnosis of congenital, cyclic or idiopathic neutropenia. In all of these conditions, it is expected that the marrow aspirate evaluation at the time of neutropenia will show a deficiency of mature neutrophils. An exception is myelokathexis, a condition with large accumulations of neutrophils with pycnotic nuclei in the marrow. Bone marrow aspirates may show some dyspoiesis of the neutrophil lineage, but abnormalities of erythropoiesis or platelet formation are, in general, inconsistent with the diagnosis of SCN.
Normal cytogenetic evaluation. The only exception being cases of well documented severe congenital neutropenia with preferably previously documented normal cytogenetic evaluation will now be enrolled in the Registry at the time of evolution to leukemia.
History of recurrent infections (i.e., severe mouth ulcers, gingivitis and sinusitis).
Age greater than three months.
Independent of hematological parameters, subjects with the following diagnoses may be included: Shwachman-Diamond syndrome (SDS), glycogen storage disease type 1b (GSD1b), Barth syndrome, and Cohen's syndrome.
Subjects with moderately severe chronic neutropenia (i.e., ANC less than 1.0x109/L) and recurrent severe infections (i.e., deep tissue infections of subcutaneous areas, lungs, liver, etc.).
Immune neutropenia with positive anti-neutrophil antibodies meeting criteria in 1, 3, 5 and 6.
All SCN subjects originally enrolled in Amgen-sponsored SCN studies.

Exclusion Criteria

Neutropenia known to be drug induced
Primary myelodysplasia
Primary leukemia
Aplastic anemia
Known HIV disease
Systemic autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus
Chemotherapy-induced neutropenia (within the last 5 years)

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

1000

Study ID:

NCT00004342

Recruitment Status:

Unknown status

Sponsor:

National Center for Research Resources (NCRR)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Dana-Farber/Boston Children¹s Cancer and Blood Disorders Center
Boston Massachusetts, 02115, United States More Info
Akiko Shimamura, MD, PhD
Contact
617-919-6109
[email protected]
University of Massachusetts
Worcester Massachusetts, 01655, United States More Info
Peter Newburger, MD
Contact
508-856-4225
[email protected]
University of Michigan
Ann Arbor Michigan, 48109, United States More Info
Kelly J. Walkovich, MD
Contact
734-647-2893
[email protected]
St. Joseph's Children's Hospital
Paterson New Jersey, 07503, United States More Info
MaryAnn Bonilla
Contact
973-754-3230
[email protected]
Caterna Lovaglio, RN/CRA
Contact
973-754-3778
[email protected]
University of Washington School of Medicine
Seattle Washington, 98195, United States More Info
David Chandler Dale
Contact
206-543-7215
Monash University
Melbourne Victoria, 3350, Australia More Info
Graham Leischke, PhD
Contact
+61 3 9902 9720
[email protected]
CancerCare Manitoba
Winnipeg Manitoba, R3E 0, Canada More Info
Bonnie Paula Cham
Contact
204-787-4147
Hospital for Sick Children
Toronto Ontario, M5G 1, Canada More Info
Yigal Dror, MD
Contact
+416-813-5630
[email protected]
Philippa McCaffrey
Contact
+416-813-8886
[email protected]
Medizinische Hochschule Hannover
Hannover , D-306, Germany More Info
Connie Zeidler, Dr.med
Contact
+49-511-532-6710
[email protected]
Sonja Klein
Contact
[email protected]
Leeds Teaching Hospitals, Yorkshire Regional Centre for Paediatric Oncology & Haematology
Leeds England, LS1 3, United Kingdom More Info
Sally Kinsey, MD
Contact
+44-113-392-8191

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Estimated Enrollment:

1000

Study ID:

NCT00004342

Recruitment Status:

Unknown status

Sponsor:


National Center for Research Resources (NCRR)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider